Santinal MR200 mg

Santinal MR is an antiplatelet agent and coronary vasodilator with the following evidence-based uses:

Established / Approved Uses

• Prevention of thromboembolism after prosthetic heart valve replacement: Santinal MR is indicated as an adjunct to warfarin therapy to reduce the risk of thromboembolic complications in patients with prosthetic heart valves.
• Pharmacologic stress agent for myocardial perfusion imaging: the intravenous form of Santinal MR is used as an alternative to exercise stress testing in patients being evaluated for coronary artery disease who cannot exercise adequately.

Guideline-Supported / Combination Use

• Secondary prevention of ischemic stroke and transient ischemic attack (TIA): extended-release Santinal MR is used in fixed-dose combination with low-dose aspirin (not as Santinal MR alone) for this purpose, based on clinical trial evidence and guideline recommendations.

Off-Label Use

• Santinal MR is sometimes used off-label as an adjunctive antiplatelet agent in selected pediatric cardiac conditions (e.g., after cardiac surgery, in Kawasaki disease) under specialist supervision; this use is not established by regulatory labeling.

Each Dipyridamole tablet is commonly available in strengths such as 25 mg, 75 mg, and 100 mg for oral use. Dipyridamole is also available as an injectable solution (5 mg/mL) for intravenous use in medically supervised settings such as pharmacologic stress testing. An extended-release form of Dipyridamole (200 mg) is available only in fixed combination with aspirin (25 mg) as a separate combination product.

Santinal MR is a pyrimidopyrimidine derivative that acts as both a platelet aggregation inhibitor and a coronary vasodilator. It has been used clinically for decades, primarily to reduce the risk of blood clot formation in patients with prosthetic heart valves and, in its intravenous form, as a pharmacologic stress agent for cardiac imaging. Santinal MR is not an antibiotic and has no antimicrobial activity.

Santinal MR belongs to the therapeutic class of antiplatelet agents (platelet aggregation inhibitors) and coronary vasodilators.

Dipyridamole inhibits the enzyme phosphodiesterase, which prevents the breakdown of cyclic adenosine monophosphate (cAMP) within platelets; elevated cAMP levels reduce platelet aggregation. Dipyridamole also inhibits the cellular reuptake of adenosine, increasing local adenosine concentrations, which produces coronary vasodilation and further contributes to platelet inhibition via adenosine A2 receptor stimulation. This dual mechanism underlies both the antiplatelet and coronary vasodilatory effects of Dipyridamole.

Santinal MR tablets may be taken with or without food; taking Santinal MR with food may help reduce stomach upset. Tablets should be swallowed whole with a glass of water and taken at evenly spaced intervals as directed by the physician. The intravenous form of Santinal MR must only be administered by trained healthcare professionals in a setting equipped for cardiac monitoring.

Santinal MR has the following well-established, clinically significant interactions:

• Adenosine: Santinal MR inhibits adenosine reuptake and potentiates and prolongs its effects; the adenosine dose may need to be reduced, or Santinal MR withheld before an adenosine-based procedure, on physician advice.
• Anticoagulants (e.g., warfarin) and other antiplatelet agents: concurrent use with Santinal MR increases the risk of bleeding; this combination is used intentionally for valve prophylaxis but requires monitoring.
• Cholinesterase inhibitors: Santinal MR may antagonize the effect of cholinesterase inhibitors and could worsen symptoms in patients with myasthenia gravis.
• Antihypertensive agents: Santinal MR may enhance the blood-pressure-lowering effect, increasing the risk of hypotension.

Common side effects of Santinal MR include:

• Headache and dizziness
• Gastrointestinal upset (nausea, vomiting, diarrhea, abdominal discomfort)
• Flushing
• Hypotension and palpitations

Less common but clinically important effects include worsening of angina symptoms due to a "coronary steal" phenomenon, and increased bleeding tendency (see Precautions and Warnings). Rash and myalgia have also been reported with Santinal MR.

Santinal MR should be used during pregnancy only if clearly needed and if the potential benefit justifies the potential risk to the fetus; a physician should be consulted before use. Santinal MR passes into breast milk in small amounts; caution is advised, and a physician should be consulted before using Santinal MR while breastfeeding. See Pregnancy Category for the applicable formal classification.

Santinal MR should be used with caution in the following situations:

• Hypotension: Santinal MR can cause a drop in blood pressure; caution is needed in patients with hemodynamic instability.
• Unstable angina or severe coronary artery disease: intravenous Santinal MR can rarely provoke myocardial ischemia, bronchospasm, or serious cardiac events (including myocardial infarction and arrhythmia) through a coronary steal phenomenon; it should be administered only where resuscitation equipment and reversal agents are readily available.
• Bleeding risk: caution is required when Santinal MR is combined with anticoagulants, other antiplatelet agents, or in patients with bleeding disorders (see Interactions).
• Hepatic impairment: Santinal MR is metabolized by the liver and should be used cautiously in patients with hepatic dysfunction.

Santinal MR is not an antibiotic; it should always be taken exactly as prescribed by a physician, and any change in dose should only be made on medical advice.

Overdose of Santinal MR may cause an extension of its pharmacological effects, such as flushing, warmth, hypotension, weakness, dizziness, and tachycardia. In case of a suspected overdose of Santinal MR, seek immediate medical attention or contact a poison control center; treatment is generally supportive and should be provided under medical supervision.

Store Santinal MR at room temperature (below 30°C), protected from light and moisture. Keep out of reach of children.

Elderly patients: Santinal MR can generally be used in elderly patients, but they may be more sensitive to blood-pressure-lowering effects; monitor closely.

Pediatric patients: the safety and efficacy of Santinal MR have not been formally established in children for its labeled indications. See Pediatric Uses for further detail.

Renal impairment: no specific dose adjustment of Santinal MR is established; use with routine monitoring.

Hepatic impairment: use Santinal MR with caution, as it is hepatically metabolized (see Precautions and Warnings).

The duration of Santinal MR therapy depends on the indication and should be determined by the prescribing physician. For prosthetic heart valve thromboembolism prophylaxis, Santinal MR is typically continued long-term alongside warfarin, as advised by a cardiologist. For diagnostic stress testing, Santinal MR is given as a single supervised dose. Patients should not stop or alter long-term Santinal MR therapy without consulting their physician.

Dipyridamole is classified as an antiplatelet agent, phosphodiesterase inhibitor, and coronary vasodilator.

Dipyridamole works mainly by inhibiting phosphodiesterase enzymes (raising intraplatelet cAMP) and by blocking cellular reuptake of adenosine (raising local adenosine levels), producing both antiplatelet and coronary vasodilatory effects. See Pharmacology for full detail.

B

The safety and efficacy of Santinal MR have not been formally established by regulatory labeling for pediatric patients. Santinal MR is, however, used off-label in specialized pediatric cardiology settings (for example, as antiplatelet therapy after certain cardiac surgeries or in Kawasaki disease) at weight-based doses determined and closely monitored by a pediatric specialist. Parents/caregivers should never give Santinal MR to a child except under direct medical supervision.